Legal Advantage Investments Inc. Sells 200 Shares of AstraZeneca PLC (NASDAQ:AZN)

Legal Advantage Investments Inc. cut its stake in AstraZeneca PLC (NASDAQ:AZN) by 4.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,950 shares of the company’s stock after selling 200 shares during the quarter. Legal Advantage Investments Inc.’s holdings in AstraZeneca were worth $259,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Brookmont Capital Management grew its stake in shares of AstraZeneca by 54.8% in the fourth quarter. Brookmont Capital Management now owns 55,985 shares of the company’s stock worth $3,668,000 after acquiring an additional 19,827 shares during the period. Mitchell & Pahl Private Wealth LLC grew its position in AstraZeneca by 5.9% during the fourth quarter. Mitchell & Pahl Private Wealth LLC now owns 13,872 shares of the company’s stock valued at $909,000 after buying an additional 771 shares during the period. ZWJ Investment Counsel Inc. grew its position in AstraZeneca by 11.4% during the fourth quarter. ZWJ Investment Counsel Inc. now owns 730,700 shares of the company’s stock valued at $47,875,000 after buying an additional 74,529 shares during the period. Koshinski Asset Management Inc. grew its position in AstraZeneca by 4.9% during the fourth quarter. Koshinski Asset Management Inc. now owns 6,933 shares of the company’s stock valued at $454,000 after buying an additional 322 shares during the period. Finally, Harbor Investment Advisory LLC grew its position in AstraZeneca by 36.5% during the fourth quarter. Harbor Investment Advisory LLC now owns 2,665 shares of the company’s stock valued at $175,000 after buying an additional 712 shares during the period. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Price Performance

AZN stock opened at $66.60 on Tuesday. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The company’s fifty day moving average price is $66.11 and its 200-day moving average price is $74.46. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The company has a market capitalization of $206.53 billion, a PE ratio of 31.87, a price-to-earnings-growth ratio of 1.04 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s revenue was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.87 earnings per share. On average, equities analysts anticipate that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on AZN shares. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, AstraZeneca has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.